^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BOS-371

    i
    Other names: BOS-371, GSK3903371
    Associations

    News

    Trials
    Company:
    Boston Pharma, GSK
    Drug class:
    IL1RAP inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    BOS-371, a monoclonal antibody against IL1RAP: Characterization in preclinical models of AML. (ASCO 2023)
    These findings demonstrate that BOS-371 binds with high affinity to IL1RAP, potently inhibits IL1 signaling and induces ADCC, leading to anti-leukemic activity in vitro and in vivo. The preclinical results support the clinical investigation of BOS-371 for the treatment of myeloid malignancies. A Phase 1 trial is currently in development.
    Preclinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IL6 (Interleukin 6) • IL1A (Interleukin 1, alpha) • IL1RAP (Interleukin 1 Receptor Accessory Protein)
    |
    BOS-371